# Weizmannia coagulans SA9: A Novel Strategy to Alleviate Type 2 Diabetes

**Authors:** Linhao Wang, Jie Wang, Yewei Tan, Changyu Cai, Xiaohua Yang, Sashuang Dong, Jiaqi Hong, Xiang Fang, Hong Wei, Zhenlin Liao

PMC · DOI: 10.3390/nu17132081 · 2025-06-23

## TL;DR

This study explores how a new probiotic, Weizmannia coagulans SA9, may help manage type 2 diabetes by improving glucose levels and gut health.

## Contribution

The novel contribution is the identification of Weizmannia coagulans SA9 as a promising probiotic for managing type 2 diabetes.

## Key findings

- W. coagulans SA9 significantly inhibits α-glucosidase and α-amylase enzymes.
- Probiotic treatment improved glucose tolerance and reduced inflammation in diabetic mice.
- The probiotic altered gut microbiota by reducing harmful bacteria and increasing beneficial ones.

## Abstract

Background: Probiotics have recently emerged as promising agents in the prevention and treatment of various human diseases. This study investigates the therapeutic potential of Weizmannia coagulans SA9 in the management of type 2 diabetes mellitus (T2DM). Methods: The in vitro antidiabetic activity of W. coagulans SA9 was primarily assessed via its α-glucosidase inhibitory capacity, complemented by metabolomic profiling to identify putative bioactive metabolites. The antidiabetic efficacy was further evaluated in a db/db mouse model, focusing on glucose tolerance, inflammatory biomarkers, and gut microbiota composition. Results: W. coagulans SA9 showed significant inhibitory effects on α-glucosidase and α-amylase, and DNJ and other active substances were detected in its culture supernatant. After 6 weeks of continuous administration, the fasting blood glucose level, glucose tolerance, and inflammation indexes of mice were significantly improved. Beneficial changes in the structure of the intestinal flora occurred after the probiotic intervention, as evidenced by a significant decrease in harmful bacteria (e.g., Aerococcus urinaeequi) and a significant enrichment of beneficial bacteria (e.g., Limosilactobacillus reuteri). Conclusions: W. coagulans SA9 exerts robust antidiabetic effects and holds promise as a novel strategy for the prevention and management of T2DM.

## Linked entities

- **Chemicals:** DNJ (PubChem CID 29435)
- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), T2DM (MONDO:0005148)
- **Species:** Aerococcus urinaeequi (taxon 51665), Limosilactobacillus reuteri (taxon 1598)

## Full-text entities

- **Genes:** Sis (sucrase isomaltase) [NCBI Gene 69983] {aka 2010204N08Rik, SI, Si-s}
- **Diseases:** inflammation (MESH:D007249), T2DM (MESH:D003924)
- **Chemicals:** glucose (MESH:D005947), DNJ (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Aerococcus urinaeequi (species) [taxon 51665]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12251212/full.md

---
Source: https://tomesphere.com/paper/PMC12251212